IRVINE, California, June 3 (TNSjou) -- The University of California Irvine campus issued the following news release:

* * *

UC Irvine study identifies serious infection risks linked to targeted cancer therapies

Proactive monitoring, management of antibody-drug side effects needed

* A UC Irvine-led study analyzed 3,511 cancer patients across six UC medical centers to examine infection-related side effects to antibody-drug conjugates, or ADCs.